Vaccine (Recombinant protein vaccine) · Immune activation, directed at Toll-like receptor 9 (TLR9) · developed by Regeneron Pharmaceuticals
Vidutolimod is a virus-like particle built from the Qbeta bacteriophage capsid that encapsulates a CpG-A oligodeoxynucleotide TLR9 agonist. The particles are taken up by antigen-presenting cells, where the oligonucleotide releases and activates intracellular TLR9 to stimulate innate immune signaling. It is studied in locally advanced basal cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
Locally Advanced Basal Cell Carcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →